Metoprolol

Metoprolol is a beta blocker, a class of drugs that oppose the action of adrenaline and related hormones on the heart, and it is described as cardioselective because it acts mainly on the beta-1 receptors that predominate in cardiac tissue rather than the beta-2 receptors of the lungs and blood vessels ^[1][2]. It has no intrinsic sympathomimetic activity, meaning it purely blocks these receptors ^[1]. The drug is a racemic mixture of two mirror-image forms and is moderately fat-soluble, a property that lets it enter the brain and may account for some of its central side effects ^[1]. It comes as two different salts, metoprolol tartrate and metoprolol succinate, formulated for immediate and extended release respectively, which are not simply interchangeable ^[1].

Metoprolol was developed in 1969 by researchers at the Swedish company Hassle, part of what became AstraZeneca, during the effort to create beta blockers that spared the lungs ^[1]. The immediate-release tartrate salt was approved in the United States in 1978 under the name Lopressor, and an extended-release succinate formulation, Toprol-XL, followed in the 1990s ^[1]. It is now a generic medicine and one of the most frequently prescribed drugs in the United States ^[1].

Metoprolol is used for a broad range of cardiovascular problems, including high blood pressure, angina, and abnormal heart rhythms, and it is given during and after a heart attack to improve outcomes ^[1]. In chronic heart failure with reduced pumping function, the extended-release form was shown in a large randomized trial to lower mortality and hospitalizations and to improve symptoms and well-being ^[3]. Beyond the heart, it is used to prevent migraine headaches and as an adjunct in managing an overactive thyroid ^[1][2]. Its clearance depends heavily on the liver enzyme CYP2D6, and genetic differences in that enzyme can markedly change how much drug a person is exposed to and how their heart rate responds ^[4].

Metoprolol is a prescription medicine on the World Health Organization's Model List of Essential Medicines, available generically as tablets and injectable solution ^[1]. Common side effects include tiredness, dizziness, slow heart rate, cold hands and feet, and, because the drug crosses into the brain, sleep disturbances such as vivid dreams and insomnia ^[1]. It should not be stopped abruptly, since sudden withdrawal can worsen angina or provoke a rapid heart rate, and it can mask the warning signs of low blood sugar in people with diabetes ^[1]. It is also banned in certain precision sports because slowing the heart and steadying tremor can improve performance ^[1].

Metoprolol is a prescription medicine. Common side effects include tiredness, a slow heart rate, cold hands and feet, dizziness, low blood pressure, vivid dreams, and low mood; some people notice reduced exercise tolerance or sexual difficulties. It should not be stopped abruptly because that can trigger rebound rapid heart rate, chest pain, or even a heart attack; the dose is tapered instead. It is avoided in very slow heart rates, high-degree heart block, decompensated heart failure, and cardiogenic shock, and used cautiously in asthma. Combining it with verapamil or diltiazem can slow the heart dangerously, and it can mask the warning signs of low blood sugar in people on insulin.

Metoprolol is cleared almost entirely by CYP2D6, which makes it unusually sensitive to inhibition of that enzyme. In a crossover study of healthy volunteers, paroxetine raised metoprolol exposure roughly three to four fold and roughly doubled its half life, with measurably deeper and longer beta blockade. Fluoxetine, bupropion, quinidine and terbinafine do the same thing, and poor CYP2D6 metabolizers behave as though they were permanently on an inhibitor.

Combining metoprolol with verapamil or diltiazem stacks negative chronotropic and inotropic effects at the AV node; severe bradycardia, heart block and cardiac decompensation have followed. Digoxin, amiodarone and other rate-slowing agents carry the same additive risk.

Stopping clonidine while beta blockade is running can produce rebound hypertension, because unopposed alpha stimulation meets blocked beta vasodilation. Epinephrine given during beta blockade can likewise drive a pressor response with reflex bradycardia. In people using insulin, beta blockade masks the adrenergic warning signs of hypoglycemia, although sweating survives.

Checking a whole stack? Run it through interactions + stacks.

Metoprolol was developed in the early 1970s by the Swedish company AB Hassle, part of the Astra group, as part of the search for a beta-blocker that would act selectively on the heart and spare the airways, improving on the non-selective propranolol and the problematic earlier cardioselective agent practolol. It reached the market later in that decade, sold as Lopressor and Betaloc, and became one of the most widely prescribed cardiovascular drugs in the world.

Its reputation was cemented by a series of major clinical trials, most notably MERIT-HF in 1999, which demonstrated that the extended-release form significantly reduced mortality in chronic heart failure, and by evidence that as a lipophilic agent it lowers sudden cardiac death after heart attack. The large POISE trial later tempered enthusiasm for routine perioperative use by showing a trade-off of fewer heart attacks but more strokes and deaths. Metabolized chiefly by the genetically variable liver enzyme CYP2D6, metoprolol is now available in immediate-release tartrate and extended-release succinate salt forms and remains a cornerstone of cardiology.

Metoprolol stands among the most rigorously validated and widely trusted drugs in all of cardiovascular medicine, a beta-blocker whose benefits have been tested in some of the largest trials ever conducted. Its landmark achievement is the MERIT-HF trial, which showed that adding extended-release metoprolol to standard therapy meaningfully improved survival in chronic heart failure, an effect that transformed how the condition is treated. Because it is fat-soluble and penetrates the brain, it is uniquely useful beyond the heart, serving as an effective and inexpensive option for migraine prevention.

Clinicians respect it as a versatile, well-tolerated agent for high blood pressure, angina, and arrhythmias, though its story is refreshingly honest about limits: the POISE trial revealed that giving it routinely around surgery reduced heart attacks but increased strokes and overall mortality, and genetic variation in CYP2D6 metabolism means people respond differently. That blend of proven benefit and clearly mapped boundaries is exactly what has kept it a first-choice drug for decades.